Multimodal Therapeutic Strategies Targeting BCAA Metabolism in Diabetic Cardiomyopathy: A Path to Cardioprotection
Cardiovascular Toxicology · 2026
DOI: 10.1007/s12012-025-10079-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Toxicology, 2026. Verfasst von Shewale Chetana und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S Narsee Monjee Institute of Management Studi…. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Amino Acids, Branched-Chain, Energy Metabolism, Myocardium. Die Arbeit nennt 164 Literaturangaben.
Abstract (Originalsprache)
A serious consequence of diabetes mellitus, diabetic cardiomyopathy (DCM) is marked by structural and functional abnormalities leading to diastolic dysfunction, eventually leading to systolic dysfunction and heart failure. Branched-chain amino acids (BCAAs), leucine, isoleucine, and valine have a dual role in cardiac metabolism. Although they are essential for mitochondrial function and protein synthesis, elevated levels of BCAA contribute to insulin resistance, stimulate mTOR signaling, and proinflammatory pathways, resulting in cardiac hypertrophy and heart failure in DCM. This review explores therapeutic approaches to target BCAA metabolism. By suppressing mTOR signaling and cardiac reprogramming, strategies such as restriction of dietary BCAA and substitution with plant-based protein can improve insulin sensitivity and cardiac reprogramming. For enhancement of BCAA catabolism, alleviation of oxidative stress, and reduction in myocardial fibrosis, pharmacological agents such as mTOR inhibitors, branched-chain α-keto acid dehydrogenase (BCKDH) activators, and fibroblast growth factor 21 (FGF21) analogs can be utilized. PPARα agonists, insulin sensitizers, can indirectly benefit cardiac health by improving glucose metabolism and systemic inflammation. While lifestyle modification, such as physical activity, enhances mitochondrial function and autophagy, novel and innovative approaches, such as leucine deprivation or L-type amino acid transporter (LAT1) inhibitors, can manage the cardiac damage arising due to BCAA. Future studies should focus on personalized and multidisciplinary treatments incorporating pharmacological and lifestyle modifications to better understand the complex function of BCAA metabolism in DCM. Advanced molecular studies and clinical trials are essential for optimizing these strategies to investigate innovative ways of cardioprotection in diabetic patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-be University, V.L. Mehta Road, Vile Parle (West)…
ORCID-Profile: Barve Kalyani
Zitieren
APA
Chetana, S., & Kalyani, B. (2026). Multimodal Therapeutic Strategies Targeting BCAA Metabolism in Diabetic Cardiomyopathy: A Path to Cardioprotection. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-025-10079-3
Vancouver
Chetana S, Kalyani B. Multimodal Therapeutic Strategies Targeting BCAA Metabolism in Diabetic Cardiomyopathy: A Path to Cardioprotection. Cardiovascular Toxicology. 2026. doi:10.1007/s12012-025-10079-3
BibTeX
@article{Chetana2026,
author = {Chetana, Shewale and Kalyani, Barve},
title = {Multimodal Therapeutic Strategies Targeting BCAA Metabolism in Diabetic Cardiomyopathy: A Path to Cardioprotection},
journal = {Cardiovascular Toxicology},
year = {2026},
doi = {10.1007/s12012-025-10079-3}
}
EUVIMED